Replies to post #84494 on Biotech Values

[rkrw]

Talecris also is facing a future threat in baxter's pivotal study for a 1/monthly, 1 injection site of IGIV. Versus the talecris injectable which is once/week with several injection sites and poor bioavailability, so higher doses needed. IGIV is Talecris's biggest product.

[DewDiligence]

Alpha-1 antitrypsin as a treatment for type-1 diabetes? OMBP.OB thinks this makes sense:

http://finance.yahoo.com/news/Omni-Bio-Announces-FDA-IND-iw-2198710823.html?x=0&.v=1

[genisi]

Talecris stopped inhaled plasma-derived AAT trials for now:

http://www.alpha-1foundation.org/news/talecris-releases-letter-to-alpha-1-community-outlining-research-strategy-including-recombinant-alpha-1-protein